Search
Search Results
##search.searchResults.foundPlural##
-
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
2964PDF: 896HTML: 1953 -
THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies
1530PDF: 539HTML: 272 -
RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM
1194PDF: 1070HTML: 203 -
THE SPECTRUM OF GENETIC DEFECTS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2245PDF: 885HTML: 2001Fig 1 Rossi: 177 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3699PDF: 1446HTML: 182 -
MUTATIONAL PROFILES OF F8 AND F9 IN A COHORT OF HAEMOPHILIA A AND HAEMOPHILIA B PATIENTS IN THE MULTI-ETHNIC MALAYSIAN POPULATION
2026PDF: 1053HTML: 718Figure 1: 155Figure 2: 170 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2132PDF: 1696HTML: 378 -
IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA
2546PDF: 1134HTML: 142 -
COEXISTENCE OF MULTIPLE GENE VARIANTS IN SOME PATIENTS WITH ERYTHROCYTOSES Multiple gene variants in erythrocytosis
847PDF: 1229HTML: 132 -
GENETIC PATHWAYS LEADING TO THERAPY-RELATED MYELOID NEOPLASMS
2585PDF: 800HTML: 5214 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2190PDF: 2026HTML: 173 -
Idiopathic pulmonary embolism in a case of severe family ANKRD26 thrombocytopenia
2141PDF: 832HTML: 928Patient’s family tree: 168 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2049PDF: 1864HTML: 348 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
3925Suppl. Files: 1119PDF: 1069Html: 177 -
HB H DISEASE CAUSED BY UNIPARENTAL DISOMY: FIRST REPORT OF THE αT-SAUDIΑ MUTATION IN THE CHINESE POPULATION
1021PDF: 604Html: 118Suppl. Files: 446 -
THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition
1346PDF: 830HTML: 135 -
DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES
1378HTML: 435PDF: 822 -
PEDIATRIC MASTOCYTOSIS: AN UPDATE Chldren' Mastocytosis
1843HTML: 1451PDF: 1086 -
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2842PDF: 848HTML: 6519Untitled: 227Untitled: 189Untitled: 205Untitled: 214 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4152PDF: 3434HTML: 204 -
Guest Editor: Pellegrino Musto REFINING HIGH-RISK MULTIPLE MYELOMA: ADVANCEMENTS IN GENOMIC, CLINICAL, AND PROGNOSTIC CRITERIA Multiple Myeloma High Risk Classificatio
2171PDF: 1588HTML: 286 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3942PDF: 1505HTML: 9188Untitled: 278Untitled: 184Untitled: 169Untitled: 164Untitled: 181Untitled: 339 -
Can Polycythemia Vera evolve from Acute Myeloid Leukemia? A Case Report Showing a Simultaneous Minor JAK2 V617F Mutated Clone, De novo polycythemia vera following AML remission
1658PDF: 749HTML: 257 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1721PDF: 841HTML: 148 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1533PDF: 944HTML: 223 -
BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN
1784PDF: 969HTML: 144 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2458HTML: 271PDF: 872 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1636PDF: 1093HTML: 119 -
FLT3 Mutated Acute Myeloid Leukemia after CD19 CAR-T Cells
952PDF: 1208HTML: 111 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2296PDF: 1326HTML: 17079Bassan Fig.1: 143Bassan Fig.2: 155Bassan Fig.4: 142Fig.3: 185 -
APPROACHING THE TARGET: THE PATH TOWARDS AN EFFECTIVE MALARIA VACCINE
2558PDF: 967HTML: 15107 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2208PDF: 1495HTML: 267 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3371PDF: 1280HTML: 2215Fi.1 Gritti.Rambaldi: 205 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3995PDF: 1053HTML: 3592Untitled: 177Cneo. Fig.1: 114Untitled: 105Untitled: 126Untitled: 133 -
The venetoclax/azacitidine combination targets the disease clone in Acute Myeloid Leukemia, being effective and safe in a patient with COVID VEN/AZA effectively targets AML clones
1242PDF: 758HTML: 316 -
CAR-T CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA CAR-T and CLL
3559PDF: 1578HTML: 80







